MUMBAI, India, Aug. 31 -- Intellectual Property India has published a patent application (202641100131 A) filed by Brahmaiah Bonthagarala; Rama Krishna Garlapati; Yerragopu. Naga Surekha; Dr. M. V. Nagabhushanam; K. Ramalingeswara Rao; Dr. Y. Ratna Sindhu; Dr. U. Neeraja Kamakshi; M. Beena Devi; Ch. Adilakshmi; and Sk. Sanjuda on August 19, 2026, for Biodegradable Polymer-Based Microspheres Of Empagliflozin For Controlled And Sustained Drug Delivery In Type Ii Diabetic Therapy.
Inventors include Brahmaiah Bonthagarala; Rama Krishna Garlapati; Yerragopu. Naga Surekha; Dr. M. V. Nagabhushanam; K. Ramalingeswara Rao; Dr. Y. Ratna Sindhu; Dr. U. Neeraja Kamakshi; M. Beena Devi; Ch. Adilakshmi; and Sk. Sanjuda.
The application for the patent was published on August 28, 2026, under issue no. 35/2026.
Abstract: The present invention relates to biodegradable polymer-based microspheres of empagliflozin designed for controlled and sustained drug delivery in the management of diabetes mellitus. The microspheres are formulated using a biodegradable polymer, preferably poly(lactic-co-glycolic acid) (PLGA), as a carrier matrix for the encapsulation of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. The formulation is prepared using an emulsion–solvent evaporation technique, wherein empagliflozin and PLGA are dissolved or dispersed in a suitable organic solvent system to form an internal phase, which is subsequently emulsified into an aqueous external phase containing a stabilizing agent under controlled homogenization conditions, followed by solvent removal to yield solidified microspheres.The resulting microspheres exhibit spherical morphology with a uniform particle size distribution suitable for pharmaceutical administration. The system demonstrates improved drug encapsulation efficiency and reduced initial burst release compared to conventional formulations, thereby enabling more controlled pharmacokinetic behavior. In vitro release studies indicate a biphasic drug release profile characterized by an initial moderate release phase followed by a sustained release phase extending up to 24 hours, attributed to diffusion and polymer matrix erosion mechanisms.The biodegradable nature of the PLGA matrix ensures gradual degradation into biocompatible by-products, eliminating the need for surgical removal or long-term accumulation concerns. The controlled release characteristics of the microsphere system are expected to maintain more stable plasma drug concentrations, potentially reducing dosing frequency and improving therapeutic outcomes. Overall, the invention provides a novel and efficient biodegradable microsphere-based delivery system for empagliflozin that enhances drug release control, improves encapsulation performance, and offers potential benefits in patient compliance and long-term management of diabetes mellitus.
Disclaimer: Curated by HT Syndication.
